<?xml version='1.0' encoding='utf-8'?>
<document id="16934427"><sentence text="Sensitive and selective liquid chromatography-mass spectrometry method for the quantification of rosiglitazone in human plasma."><entity charOffset="97-110" id="DDI-PubMed.16934427.s1.e0" text="rosiglitazone" /></sentence><sentence text="A sensitive and selective high-performance liquid chromatography-electrospray ionisation-tandem mass spectrometry (HPLC-ESI-MS-MS) method for determination of rosiglitazone in human plasma has been developed"><entity charOffset="159-172" id="DDI-PubMed.16934427.s2.e0" text="rosiglitazone" /></sentence><sentence text=" After the addition of the internal standard, plasma samples were precipitated by acetonitrile"><entity charOffset="82-94" id="DDI-PubMed.16934427.s3.e0" text="acetonitrile" /></sentence><sentence text=" The compounds were separated on a proC18 column using a mixture of ammonium acetate buffer (0"><entity charOffset="68-84" id="DDI-PubMed.16934427.s4.e0" text="ammonium acetate" /></sentence><sentence text="02 M, pH 6" /><sentence text="5) and acetonitrile (in the ratio of 47:53, v/v) as mobile phase"><entity charOffset="7-19" id="DDI-PubMed.16934427.s6.e0" text="acetonitrile" /></sentence><sentence text=" A Finnigan LCQdeca plus ion trap mass spectrometer connected to a Finnigan Surveyor HPLC was used to develop and validate the method" /><sentence text=" Linearity was established for the range of concentrations 1-1000 ng/ml with a coefficient of determination (r(2)) of 0" /><sentence text="999" /><sentence text=" The intra-day accuracy for rosiglitazone ranged from 110"><entity charOffset="28-41" id="DDI-PubMed.16934427.s10.e0" text="rosiglitazone" /></sentence><sentence text="0 to 99" /><sentence text="2% at low, medium and high levels" /><sentence text=" The inter-day accuracy was less than 15%" /><sentence text=" The lower limit of quantitation (LLOQ) was identified reproducible at 1" /><sentence text="0 ng/ml with a precision of 5" /><sentence text="7%" /><sentence text=" After validation, the method was used to study the pharmacokinetic profile of rosiglitazone in five healthy volunteers after administration of a single oral dose (4"><entity charOffset="79-92" id="DDI-PubMed.16934427.s17.e0" text="rosiglitazone" /></sentence><sentence text="0mg)" /><sentence text=" The proposed method enabled the unambiguous evaluation and quantitation of rosiglitazone for pharmacokinetic, bioavailability or drug-drug interaction studies"><entity charOffset="76-89" id="DDI-PubMed.16934427.s19.e0" text="rosiglitazone" /></sentence><sentence text=" A possible chromatography peak (m/z 121, its parent ion m/z 344) of N-demethyl rosiglitazone was observed at 3"><entity charOffset="69-93" id="DDI-PubMed.16934427.s20.e0" text="N-demethyl rosiglitazone" /></sentence><sentence text="49 min during determining rosiglitazone"><entity charOffset="26-39" id="DDI-PubMed.16934427.s21.e0" text="rosiglitazone" /></sentence><sentence text=" This may be also a potential method for simultaneous determination of rosiglitazone and its metabolite N-demethyl rosiglitazone concentrations in plasma"><entity charOffset="71-84" id="DDI-PubMed.16934427.s22.e0" text="rosiglitazone" /><entity charOffset="104-128" id="DDI-PubMed.16934427.s22.e1" text="N-demethyl rosiglitazone" /><pair ddi="false" e1="DDI-PubMed.16934427.s22.e0" e2="DDI-PubMed.16934427.s22.e0" /><pair ddi="false" e1="DDI-PubMed.16934427.s22.e0" e2="DDI-PubMed.16934427.s22.e1" /></sentence><sentence text="" /></document>